Meleti M, Cassi D, Vescovi P, Setti G, Pertinhez TA, Pezzi ME. Salivary biomarkers for diagnosis of systemic diseases and malignant tumors. A systematic review. Med Oral Patol Oral Cir Bucal. 2020 Mar 1;25 (2):e299-310.

 

doi:10.4317/medoral.23355

https://dx.doi.org/doi:10.4317/medoral.23355

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1. Aro K, Wei F, Wong DT, Tu M. Saliva Liquid Biopsy for Point-of-Care Applications. Front Public Health. 2017;5:77.

https://doi.org/10.3389/fpubh.2017.00077

PMid:28443278 PMCid:PMC5387045

2. Yager P, Domingo GJ, Gerdes J. Point-of-Care Diagnostics for Global Health. Annu Rev Biomed Eng. 2008;10:107-44.

https://doi.org/10.1146/annurev.bioeng.10.061807.160524

PMid:18358075 

3. Kaczor-Urbanowicz KE, MartinCarreras-Presas C, Aro K, Tu M, Garcia-Godoy F, Wong DT. Saliva diagnostics - Current views and directions. Exp Biol Med. 2017;242:459-72.

https://doi.org/10.1177/1535370216681550

PMid:27903834 PMCid:PMC5367650

4. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools

5. Phillips B et al. Oxford Centre for Evidence-based Medicine-Levels of Evidence. 2009. Retrieved from http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/

6. Feng S, Huang S, Lin D, Chen G, Xu Y, Li Y, et al. Surface-enhanced Raman spectroscopy of saliva proteins for the noninvasive differentiation of benign and malignant breast tumors. Int J Nanomedicine. 2015;10:537-47.

https://doi.org/10.2147/IJN.S71811

PMid:25609959 PMCid:PMC4298339

7. Laidi F, Bouziane A, Zaoui F. Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status. Onco Targets Ther. 2014;7:1285-89.

https://doi.org/10.2147/OTT.S64230

PMid:25053886 PMCid:PMC4105270

8. Zhang L, Xiao H, Zhou H, Santiago S, Lee JM, Garon EB et al. Development of transcriptomic biomarker signature in human saliva to detect lung cancer. Cell Mol Life Sci. 2012;69:3341-50.

https://doi.org/10.1007/s00018-012-1027-0

PMid:22689099 PMCid:PMC4121486

9. Koizumi T, Shetty V, Yamaguchi M. Salivary cytokine panel indicative of non-small cell lung cancer. J Int Med Res. 2018;46:3570-82.

https://doi.org/10.1177/0300060518775563

PMid:29916282 PMCid:PMC6136026

10. Wei F, Lin CC, Joon A et al. Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer. Am J Respir Crit Care Med. 2014;190:1117-26.

https://doi.org/10.1164/rccm.201406-1003OC

PMid:25317990 PMCid:PMC5447327

11. Yang J, Mu X, Wang Y, Zhu D, Zhang J, Liang C, Chen B et al. Dysbiosis of the Salivary Microbiome Is Associated With Non-smoking Female Lung Cancer and Correlated With Immunocytochemistry Markers. Front Oncol. 2018;8:520.

https://doi.org/10.3389/fonc.2018.00520

PMid:30524957 PMCid:PMC6256243

12. Zhang L, Farrell JJ, Zhou H, Elashoff D, Akin D, Park NH, et al. Salivary Transcriptomic Biomarkers for Detection of Resectable Pancreatic Cancer. Gastroenterology. 2010;138:949-57.

https://doi.org/10.1053/j.gastro.2009.11.010

PMid:19931263 PMCid:PMC2831159

13. Xie Z, Yin X, Gong B, et al. Salivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancer. Cancer Prev Res. 2015;8:165-3.

https://doi.org/10.1158/1940-6207.CAPR-14-0192

PMid:25538087 

14. Holten-Andersen L, Christensen IJ, Jensen SB, Reibel J, Laurberg S, Nauntofte B, et al. Saliva and plasma TIMP-1 in patients with colorectal cancer: a prospective study. Scand J Gastroenterol. 2012;47:1234-41.

https://doi.org/10.3109/00365521.2012.711855

PMid:22871105 

15. Shu J, Yu H, Li X, Zhang D, Liu X, Du H. Salivary glycopatterns as potential biomarkers for diagnosis of gastric cancer. Oncotarget. 2017;8:35718-27.

https://doi.org/10.18632/oncotarget.16082

PMid:28415698 PMCid:PMC5482611

16. Sun JH, Li XL, Yin J, Li YH, Hou BX, Zhang Z. A screening method for gastric cancer by oral microbiome detection. Oncol Rep. 2018;39:2217-24.

https://doi.org/10.3892/or.2018.6286

PMid:29498406 

17. Li F, Yoshizawa JM, Kim KM, Kanjanapangka J, Grogan TR, Wang X, et al. Discovery and Validation of Salivary Extracellular RNA Biomarkers for Noninvasive Detection of Gastric Cancer. Clin Chem. 2018;64:1513-21.

https://doi.org/10.1373/clinchem.2018.290569

PMid:30097497 

18. Masters JM, Noyce AJ, Warner TT, Giovannoni G, Proctor GB. Elevated salivary protein in Parkinson's disease and salivary DJ-1 as a potential marker of disease severity. Parkinsonism relat disord. 2015;21:1251-5.

https://doi.org/10.1016/j.parkreldis.2015.07.021

PMid:26231472 

19. Ahmadi-Motamayel F, Goodarzi MT, Tarazi S, Vahabian M. Evaluation of salivary acetylcholinesterase and pseudocholinesterase in patients with Alzheimer's disease: A case-control study. Spec Care Dentist. 2019;39:39-44.

https://doi.org/10.1111/scd.12342

PMid:30536408 

20. Mirzaii-Dizgah I, Riahi E. Salivary high-sensitivity cardiac troponin T levels in patients with acute myocardial infarction. Oral Dis. 2013;19:180-4.

https://doi.org/10.1111/j.1601-0825.2012.01968.x

PMid:22834943 

21. Mirzaii-Dizgah I, Jafari-Sabet M. Unstimulated whole saliva creatine phosphokinase in acute myocardial infarction. Oral Dis. 2011;17:597-600.

https://doi.org/10.1111/j.1601-0825.2011.01817.x

PMid:21635668 

22. Mirzaii-Dizgah I, Hejazi SF, Riahi E, Salehi MM. Saliva-based creatine kinase MB measurement as a potential point-of-care testing for detection of myocardial infarction. Clin Oral Investig. 2012;16:775-9.

https://doi.org/10.1007/s00784-011-0578-z

PMid:21681388 

23. Floriano PN, Christodoulides N, Miller CS, Ebersole JL, Spertus J, Rose BG, et al. Use of Saliva-Based Nano-Biochip Tests for Acute Myocardial Infarction at the Point of Care: A Feasibility Study. Clin chem. 2009;55:1530-8.

https://doi.org/10.1373/clinchem.2008.117713

PMid:19556448 

24. Mirzaii-Dizgah I, Riahi E. Serum and Saliva Levels of Cathepsin L in Patients with Acute Coronary Syndrome. J Contemp Dent Pract. 2011;12:114-9.

https://doi.org/10.5005/jp-journals-10024-1019

PMid:22186754 

25. Wu ZZ, Wang JG, Zhang XL. Diagnostic model of saliva protein finger print analysis of patients with gastric cancer. World journal of gastroenterology. 2009;15:865-70.

https://doi.org/10.3748/wjg.15.865

PMid:19230049 PMCid:PMC2653388

26. Giusti L, Baldini C, Ciregia F, Giannaccini G, Giacomelli C, De Feo F, et al. Is GRP78/BiP a potential salivary biomarker in patients with rheumatoid arthritis? Proteomics Clinical Appl. 2010;4:315-24.

https://doi.org/10.1002/prca.200900082

PMid:21137052 

27. Streckfus C, Bigler L, Tucci M, Thigpen JT. A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma. Cancer Invest. 2000;18:101-9.

https://doi.org/10.3109/07357900009038240

PMid:10705871 

28. Streckfus C, Bigler L. The use of soluble, salivary c-erbB-2 for the detection and post-operative follow-up of breast cancer in women: the results of a five-year translational research study. Adv Dent Res. 2005;18:17-24.

https://doi.org/10.1177/154407370501800105

PMid:15998939 

29. Turan T, Demir S, Aybek H, Atahan O, Tuncay OL, Aybek Z, et al. Free and Total Prostate-Specific Antigen Levels in Saliva and the Comparison with Serum Levels in Men. Eur Urol. 2000;38:550-4.

https://doi.org/10.1159/000020354

PMid:11096235 

30. Streckfus CF, Bigler LR, Zwick M. The use of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to detect putative breast cancer markers in saliva: A feasibility study. J Oral Pathol Med. 2006;35:292-300.

https://doi.org/10.1111/j.1600-0714.2006.00427.x

PMid:16630293 

31. Brooks MN, Wang J, Li Y, Zhang R, Elashoff D, Wong DT. Salivary protein factors are elevated in breast cancer patients. Mol Med Rep. 2008;1:375-8.

https://doi.org/10.3892/mmr.1.3.375

PMid:19844594 PMCid:PMC2763326

32. Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A. Correlation of serum and salivary CA15-3 levels in patients with breast cancer. Med Oral Patol Oral Cir Bucal. 2009;14:521-4.

https://doi.org/10.4317/medoral.14.e521

PMid:19680209 

33. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6:78-95.

https://doi.org/10.1007/s11306-009-0178-y

PMid:20300169 PMCid:PMC2818837

34. Rao PV, Reddy AP, Lu X, Dasari S, Krishnaprasad A, Biggs E et al. Proteomic identification of salivary biomarkers of type-2 diabetes. J Proteome Res. 2009;8:239-45.

https://doi.org/10.1021/pr8003776

PMid:19118452 

35. Pandeshwar P, Das R. Role of oral fluids in DNA investigations. J Forensic Leg Med. 2014;22:45-50.

https://doi.org/10.1016/j.jflm.2013.12.007

PMid:24485421 

36. Valentini A, Miquel C, Nawaz MA, Bellemain E, Coissac E, Pompanon F et al. New perspectives in diet analysis based on DNA barcoding and parallel pyrosequencing: the trnL approach. Mol Ecol Resour. 2009;9:51-60.

https://doi.org/10.1111/j.1755-0998.2008.02352.x

PMid:21564566 

37. Vivacqua G, Suppa A, Mancinelli R, Belvisi D, Fabbrini A, Costanzo M, et al. Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy. Parkinsonism Relat Disord. 2019.

https://doi.org/10.1016/j.parkreldis.2019.02.014

PMid:30796010 

38. Marksteiner J, Oberacher H, Humpel C. Acyl-Alkyl Phosphatidlycholines are Decreased in Saliva of Patients with Alzheimer's Disease as Identified by Targeted Metabolomics. J Alzheimers Dis. 2019;68:583-89.

https://doi.org/10.3233/JAD-181278

PMid:30814361 

39. Julious SA. Sample sizes for clinical trials with normal data. Stat Med. 2004;23:1921-86.

https://doi.org/10.1002/sim.1783

PMid:15195324 

40. Pu D, Liang H, Wei F et al. Evaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: A pilot study. Thorac Cancer. 2016;7:428-36.

https://doi.org/10.1111/1759-7714.12350

PMid:27385985 PMCid:PMC4930962

41. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceut Statist. 2005;4:287-91.

https://doi.org/10.1002/pst.185

42. Faggion CM Jr. Evaluating the Risk of Bias of a Study. J Evid Based Dent Pract. 2015;15:164-70.

https://doi.org/10.1016/j.jebdp.2015.09.002

PMid:26698002 

43. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359-86.

https://doi.org/10.1002/ijc.29210

PMid:25220842 

44. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.

https://doi.org/10.3322/caac.21262

PMid:25651787 

45. Layke JC, Lopez PP. Gastric Cancer: Diagnosis and Treatment Options. Am Fam Physician. 2004;69:1133-40.

PMid:15023013

46. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24:4846-61.

https://doi.org/10.3748/wjg.v24.i43.4846

PMid:30487695 PMCid:PMC6250924

47. Chen Y, Cheng S, Zhang A, Song J, Chang J, Wang K, et al. Salivary Analysis Based on Surface Enhanced Raman Scattering Sensors Distinguishes Early and Advanced Gastric Cancer Patients from Healthy Persons. J Biomed Nanotechnol. 2018;14:1773-84.

https://doi.org/10.1166/jbn.2018.2621

PMid:30041723 

48. Shu J, Yu H, Du H, Zhang J, Zhang K, Li X. Identification of N- and O-linked glycans recognized by AAL in saliva of patients with atrophic gastritis and gastric cancer. Cancer Biomark. 2018;22:1-13.

https://doi.org/10.3233/CBM-171087

PMid:29865036 

49. Xiao H, Zhang Y, Kim Y, Kim S, Kim JJ, Kim KM, et al. Differential Proteomic Analysis of Human Saliva using Tandem Mass Tags Quantification for Gastric Cancer Detection. Sci Rep. 2016;6:22165.

https://doi.org/10.1038/srep22165

PMid:26911362 PMCid:PMC4766442

50. Lee YH, Wong DT. Saliva: an emerging biofluid for early detection of diseases. Am J Dent. 2009;22:241-8.

PMid:19824562

51. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010;133:713-26.

https://doi.org/10.1093/brain/awq008

PMid:20157014 PMCid:PMC2842513

52. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376:1094-108.

https://doi.org/10.1016/S0140-6736(10)60826-4

PMid:20870100

53. Javaid MA, Ahmed AS, Durand R, Tran SD. Saliva as a diagnostic tool for oral and systemic diseases. J Oral Biol Craniofac Res. 2016;6:67-76.

https://doi.org/10.1016/j.jobcr.2015.08.006

PMid:26937373 PMCid:PMC4756071

54. Xiao H, Zhang L, Zhou H, Lee JM, Garon EB, Wong DT. Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol Cell Proteomics. 2012;11:M111.012112.

https://doi.org/10.1074/mcp.M111.012112

PMid:22096114 PMCid:PMC3277759

55. Lee YH, Kim JH, Zhou H, Kim BW, Wong DT. Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma. J Mol Med. 2012;90:427-34.

https://doi.org/10.1007/s00109-011-0829-0

PMid:22095100 

56. Zhang L, Xiao H, Karlan S, Zhou H, Gross J, Elashoff D, et al. Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One. 2010;5:e15573.

https://doi.org/10.1371/journal.pone.0015573

PMid:21217834 PMCid:PMC3013113

57. Li X, Yang T, Lin J. Spectral analysis of human saliva for detection of lung cancer using surface-enhanced Raman spectroscopy. J Biomed Opt. 2012;17:037003.

https://doi.org/10.1117/1.JBO.17.3.037003

PMid:22502575 

58. De Abreu Pereira D, Areias VR, Franco MF, Benitez MC, do Nascimento CM, de Azevedo CM, et al. Measurement of HER2 in saliva of women in risk of breast cancer. Pathol Oncol Res. 2013;19:509-13.

https://doi.org/10.1007/s12253-013-9610-8

PMid:23479082 

59. Chen D, Song N, Ni R, Zhao J, Hu J, Lu Q, et al. Saliva as a sampling source for the detection of leukemic fusion transcripts. J Transl Med. 2014;12:321.

https://doi.org/10.1186/s12967-014-0321-z

PMid:25407125 PMCid:PMC4243783

60. Cheng F, Wang Z, Huang Y, Duan Y, Wang X. Investigation of salivary free amino acid profile for early diagnosis of breast cancer with ultra performance liquid chromatography-mass spectrometry. Clin Chim Acta. 2015;447:23-31.

https://doi.org/10.1016/j.cca.2015.05.008

PMid:25987308 

61. Humeau M, Vignolle-Vidoni A, Sicard F, Martins F, Bournet B, Buscail L. Salivary MicroRNA in Pancreatic Cancer Patients. PLoS One. 2015;10:e0130996.

https://doi.org/10.1371/journal.pone.0130996

PMid:26121640 PMCid:PMC4486170

62. Yan X, Yang M, Liu J, Gao R, Hu J, Li J, et al. Discovery and validation of potential bacterial biomarkers for lung cancer. Am J Cancer Res. 2015;5:3111-22.

PMid:26693063

63. Delmonico L, Moreira Ados S, Franco MF, Esteves EB, Scherrer L, Gallo CV, et al. CDKN2A (p14(ARF)/p16(INK4a)) and ATM promoter methylation in patients with impalpable breast lesions. Hum Pathol. 2015;46:1540-7.

https://doi.org/10.1016/j.humpath.2015.06.016

PMid:26255234 

64. Takayama T, Tsutsui H, Shimizu I, Toyama T, Yoshimoto N, Endo Y, et al. Diagnostic approach to breast cancer patients based on target metabolomics in saliva by liquid chromatography with tandem mass spectrometry. Clin Chim Acta. 2016;452:18-26.

https://doi.org/10.1016/j.cca.2015.10.032

PMid:26523874 

65. Torres PJ, Fletcher EM, Gibbons SM, Bouvet M, Doran KS, Kelley ST. Characterization of the salivary microbiome in patients with pancreatic cancer. PeerJ. 2015;3:e1373.

https://doi.org/10.7717/peerj.1373

PMid:26587342 PMCid:PMC4647550

66. Wood N, Streckfus CF. The Expression of Lung Resistance Protein in Saliva: A Novel Prognostic Indicator Protein for Carcinoma of the Breast. Cancer Invest. 2015;33:510-5.

https://doi.org/10.3109/07357907.2015.1081920

PMid:26506284 

67. Tsutsui H, Mochizuki T, Inoue K, Toyama T, Yoshimoto N, Endo Y, et al. High-throughput LC-MS/MS based simultaneous determination of polyamines including N-acetylated forms in human saliva and the diagnostic approach to breast cancer patients. Anal Chem. 2013;85:11835-42.

https://doi.org/10.1021/ac402526c

PMid:24274257 

68. Xie Z, Chen X, Li J, Guo Y, Li H, Pan X, et al. Salivary HOTAIR and PVT1 as novel biomarkers for early pancreatic cancer. Oncotarget. 2016;7:25408-19.

https://doi.org/10.18632/oncotarget.8323

PMid:27028998 PMCid:PMC5041913

69. Zhong L, Cheng F, Lu X, Duan Y, Wang X. Untargeted saliva metabonomics study of breast cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Talanta. 2016;158:351-60.

https://doi.org/10.1016/j.talanta.2016.04.049

PMid:27343615 

70. Machida T, Tomofuji T, Maruyama T, Yoneda T, Ekuni D, Azuma T et al. miR‑1246 and miR‑4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer. Oncol Rep. 2016;36:2375-81.

https://doi.org/10.3892/or.2016.5021

PMid:27573701 

71. Liu HJ, Guo YY, Li DJ. Predicting novel salivary biomarkers for the detection of pancreatic cancer using biological feature-based classification. Pathol Res Pract. 2017;213:394-99.

https://doi.org/10.1016/j.prp.2016.09.017

PMid:28283209 

72. Bel'skaya L. The activity of metabolic enzymes in the saliva of lung cancer patients. Natl J Physiol Pharm Pharmacol. 2017;7:646-53.

https://doi.org/10.5455/njppp.2017.7.0204402032017

73. Sun Y, Liu S, Qiao Z, Shang Z, Xia Z, Niu X, et al. Systematic comparison of exosomal proteomes from human saliva and serum for the detection of lung cancer. Anal Chim Acta. 2017;982:84-95.

https://doi.org/10.1016/j.aca.2017.06.005

PMid:28734369 

74. Laidi F, Bouziane A, Errachid A, Zaoui F. Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening. Asian Pac J Cancer Prev. 2016;17:335-9.

https://doi.org/10.7314/APJCP.2016.17.1.335

PMid:26838233 

75. Hernández-Arteaga A, de Jesús Zermeño Nava J, Kolosovas-Machuca ES, Velázquez-Salazar J, et al. Diagnosis of breast cancer by analysis of sialic acid concentrations in human saliva by surface-enhanced Raman spectroscopy of silver nanoparticles. Nano Res. 2017;10:3662-70.

https://doi.org/10.1007/s12274-017-1576-5

76. Cavaco C, Pereira JAM, Taunk K, Taware R, Rapole S, Nagarajaram H, et al. Screening of salivary volatiles for putative breast cancer discrimination: an exploratory study involving geographically distant populations. Anal Bioanal Chem. 2018;410:4459-68.

https://doi.org/10.1007/s00216-018-1103-x

PMid:29732495 

77. Zermeño-Nava JJ, Martínez-Martínez MU, Rámirez-de-Ávila AL, Hernández-Arteaga AC, García-Valdivieso MG, Hernández-Cedillo A, et al. Determination of sialic acid in saliva by means of surface-enhanced Raman spectroscopy as a marker in adnexal mass patients: ovarian cancer vs benign cases. J Ovarian Res. 2018;11:61.

https://doi.org/10.1186/s13048-018-0433-9

PMid:30041680 PMCid:PMC6058371

78. Tajmul M, Parween F, Singh L, Mathur SR, Sharma JB, Kumar S, et al. Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer. Int J Biol Macromol. 2018;108:503-14.

https://doi.org/10.1016/j.ijbiomac.2017.12.014

PMid:29222021 

79. Zhang J, Zhong Y, Zhang P, Du H, Shu J, Liu X, et al. Identification of abnormal fucosylated-glycans recognized by LTL in saliva of HBV-induced chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Glycobiology. 2019;29:242-59.

https://doi.org/10.1093/glycob/cwy108

PMid:30535277 

80. Xie Z, Zhou F, Yang Y, Li L, Lei Y, Lin X, et al. Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma. EBioMedicine. 2018;33:57-67.

https://doi.org/10.1016/j.ebiom.2018.06.026

PMid:30045829 PMCid:PMC6085584

81. Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, et al. Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain. 2011;134:e178.

https://doi.org/10.1093/brain/awr015

PMid:21349902 PMCid:PMC3122368

82. Tsuruoka M, Hara J, Hirayama A, Sugimoto M, Soga T, Shankle WR, et al. Capillary electrophoresis-mass spectrometry-based metabolome analysis of serum and saliva from neurodegenerative dementia patients. Electrophoresis. 2013;34:2865-72.

https://doi.org/10.1002/elps.201300019

PMid:23857558 

83. Al-Nimer MS, Mshatat SF, Abdulla HI. Saliva α-Synuclein and A High Extinction Coefficient Protein: A Novel Approach in Assessment Biomarkers of Parkinson's Disease. N Am J Med Sci. 2014;6:633-7.

https://doi.org/10.4103/1947-2714.147980

PMid:25599051 PMCid:PMC4290052

84. Liang Q, Zhang T and Jiang Y, et al. Metabolomics-Based Screening of Salivary Biomarkers for Early Diagnosis of Alzheimer's Disease. RSC Adv. 2015;5:96074-9.

https://doi.org/10.1039/C5RA19094K

85. Liang Q, Liu H, Li X, et al. High-throughput metabolomics analysis discovers salivary biomarkers for predicting mild cognitive impairment and Alzheimer's disease. RSC Adv. 2016;6:75499-504.

https://doi.org/10.1039/C6RA16802G

86. Yilmaz A, Geddes T, Han B, Bahado-Singh RO, Wilson GD, Imam K, et al. Diagnostic Biomarkers of Alzheimer's Disease as Identified in Saliva using 1H NMR-Based Metabolomics. Alzheimers Dis. 2017;58:355-9.

https://doi.org/10.3233/JAD-161226

PMid:28453477 

87. Ashton NJ, Ide M, Schöll M, Blennow K, Lovestone S, Hye A, et al. No association of salivary total tau concentration with Alzheimer's disease. Neurobiol Aging. 2018;70:125-7.

https://doi.org/10.1016/j.neurobiolaging.2018.06.014

PMid:30007161 

88. Cao Z, Wu Y, Liu G, Jiang Y, Wang X, Wang Z, et al. α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson's disease. Neurosci Lett. 2019;696:114-20.

https://doi.org/10.1016/j.neulet.2018.12.030

PMid:30579996 

89. Song W, Kothari V, Velly AM, Cressatti M, Liberman A, Gornitsky M, et al. Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson's disease. Mov Disord. 2018;33:583-91.

https://doi.org/10.1002/mds.27328

PMid:29488275 

90. Manconi B, Liori B, Cabras T, Vincenzoni F, Iavarone F, Lorefice L, et al. Top-down proteomic profiling of human saliva in multiple sclerosis patients. J Proteomics. 2018;187:212-22.

https://doi.org/10.1016/j.jprot.2018.07.019

PMid:30086402 

91. Buduneli E, Mäntylä P, Emingil G, Tervahartiala T, Pussinen P, Barış N, et al. Acute myocardial infarction is reflected in salivary matrix metalloproteinase-8 activation level. J Periodontol. 2011;82:716-25.

https://doi.org/10.1902/jop.2010.100492

PMid:21091346 

92. Silva DG, Stevens RH, Macedo JM, Hirata R, Pinto AC, Alves LM, et al. Higher levels of salivary MUC5B and MUC7 in individuals with gastric diseases who harbor Helicobacter pylori. Arch Oral Biol. 2009;54:86-90.

https://doi.org/10.1016/j.archoralbio.2008.08.003

PMid:18817906 

93. Mirzaii-Dizgah I, Riahi E. Salivary troponin I as an indicator of myocardial infarction. Indian J Med Res. 2013;138:861-5.

PMid:24521627

94. Adornetto G, Fabiani L, Volpe G, De Stefano A, Martini S, Nenna R, et al. An electrochemical immunoassay for the screening of celiac disease in saliva samples. Anal Bioanal Chem. 2015;407:7189-96.

https://doi.org/10.1007/s00216-015-8884-y

PMid:26168969 

95. Gang Cao, Maowen Chen, Yuanxiang Chen, Zufang Huang, Jinyong Lin, Jia Lin, et al. A potential method for non-invasive acute myocardial infarction detection based on saliva Raman spectroscopy and multivariate analysis. Laser Phys. 2015;12:125702.

https://doi.org/10.1088/1612-2011/12/12/125702

96. Giusti L, Sernissi F, Donadio E, et al. Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients. J Transl Med. 2016;14:262.

https://doi.org/10.1186/s12967-016-1023-5

PMid:27608975 PMCid:PMC5015208

97. Lu C, Hou X, Li M., Wang L, Zeng P, Jia H, et al Detection of AMA-M2 in human saliva: Potentials in diagnosis and monitoring of primary biliary cholangitis. Sci Rep. 2017;7:796.

https://doi.org/10.1038/s41598-017-00906-1

PMid:28400582 PMCid:PMC5429755

98. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

https://doi.org/10.1371/journal.pmed.1000097

PMid:19621072 PMCid:PMC2707599